Immunovia completes analytical validation of its next-generation pancreatic cancer test

LUND, Sweden, Oct. 2, 2024 /PRNewswire/ — Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation…